The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•23 February 2026•

1 min read

Arcus Biosciences Reports Positive Phase 1/1b Data for Kidney Cancer Drug Casdatifan

Key Facts

1Arcus Biosciences announced new efficacy data for Casdatifan showing progression-free survival beyond one year.

2The Phase 1/1b ARC-20 study targets patients with late-line metastatic clear cell renal cell carcinoma (ccRCC).

Arcus Biosciences (NYSE: RCUS) announced promising new efficacy data for its drug candidate Casdatifan, a HIF-2a inhibitor aimed at treating kidney cancer. Results from the Phase 1/1b ARC-20 study demonstrated that patients with late-line metastatic clear cell renal cell carcinoma achieved progression-free survival for over a year. The company highlighted the drug's potential to become a best-in-class therapy within its category due to its significant therapeutic impact. These findings were presented as part of an update on the company's oncology pipeline, focusing on late-stage clinical outcomes. Investors reacted positively to the news, as long-term survival benefits in advanced cancer stages often signal high commercial potential. The data reinforces Arcus Biosciences' position in the competitive oncology market and its commitment to innovative cancer treatments.